A new study suggests Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million—about 2% of the overall costs in the first year. The study, conducted by Georgetown Lombardi Comprehensive Cancer Center and NCI researchers, was published in JNCI.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
